Cover Image
Market Research Report

Global Diabetes Care Drugs Market - Growth, Trends and Forecast (2019 - 2024)

Published by Mordor Intelligence LLP Product code 390670
Published Content info 95 Pages
Delivery time: 2-3 business days
Price
Back to Top
Global Diabetes Care Drugs Market - Growth, Trends and Forecast (2019 - 2024)
Published: February 1, 2019 Content info: 95 Pages
Description

Market Overview

  • The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
  • North America dominates the market, followed by Asia-Pacific.
  • Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body's cells do not respond properly to insulin (known as Type 2 diabetes), or both.
  • Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.

Scope of the Report

The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.

Key Market Trends

Rising Prevalence of Diabetes

  • As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
  • Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
  • Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
  • Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
  • The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.

The United States Leads the Diabetes Drugs Market in North America

  • In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
  • In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market.

  • Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.
  • In 2015 and 2016, Lantus global sales were down by 11%, due to competition from other new drugs, biosimilars, and its own brand Toujeo.
  • September 2017: Insulin Tregopil, the first Oral Insulin, was under development by Biocon India, which is supported by JDRF.
  • March 2017: Zynquista (Sotagliflozin) was the first oral anti-diabetic drug approved in the United States for use by adults with Type 1 diabetes.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 55895

Table of Contents

1. INTRODUCTION

  • 1.1. Study Deliverables
  • 1.2. Study Assumptions
  • 1.3. Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1. Market Overview
  • 4.2. Drivers
  • 4.3. Restraints
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Consumers
    • 4.4.3. Threat of New Entrants
    • 4.4.4. Threat of Substitute Products and Services
    • 4.4.5. Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1. By Drug
    • 5.1.1. Oral Anti-diabetic drugs (Value and Volume 2012-2024)
      • 5.1.1.1. Biguanides
      • 5.1.1.1.1. Metformin
      • 5.1.1.2. Alpha-Glucosidase Inhibitors
      • 5.1.1.3. Dopamine -D2 Receptor Agonist
      • 5.1.1.3.1. Cycloset (Bromocriptin)
      • 5.1.1.4. Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
      • 5.1.1.4.1. Invokana (Canagliflozin)
      • 5.1.1.4.2. Jardiance (Empagliflozin)
      • 5.1.1.4.3. Farxiga/Forxiga (Dapagliflozin)
      • 5.1.1.4.4. Suglat (Ipragliflozin)
      • 5.1.1.5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • 5.1.1.5.1. Januvia (Sitagliptin)
      • 5.1.1.5.2. Onglyza (Saxagliptin)
      • 5.1.1.5.3. Tradjenta (Linagliptin)
      • 5.1.1.5.4. Vipidia/Nesina (Alogliptin)
      • 5.1.1.5.5. Galvus (Vildagliptin)
      • 5.1.1.6. Sulfonylureas
      • 5.1.1.7. Meglitinides
    • 5.1.2. Insulins (Value and Volume 2012-2024)
      • 5.1.2.1. Basal or Long-acting Insulin
      • 5.1.2.1.1. Lantus (Insulin Glargine)
      • 5.1.2.1.2. Levemir (Insulin Detemir)
      • 5.1.2.1.3. Toujeo (Insulin Glargine)
      • 5.1.2.1.4. Tresiba (Insulin Degludec)
      • 5.1.2.1.5. Basaglar (Insulin Glargine)
      • 5.1.2.2. Bolus or Fast-acting Insulin
      • 5.1.2.2.1. NovoRapid/Novolog (Insulin Aspart)
      • 5.1.2.2.2. Humalog (Insulin Lispro)
      • 5.1.2.2.3. Apidra (Insulin Glulisine)
      • 5.1.2.3. Traditional Human Insulin
      • 5.1.2.3.1. Novolin/Actrapid/Insulatard
      • 5.1.2.3.2. Humulin
      • 5.1.2.3.3. Insuman
      • 5.1.2.4. Biosimilar Insulin
      • 5.1.2.4.1. Insulin Glargine Biosimilars
      • 5.1.2.4.2. Human Insulin Biosimilars
    • 5.1.3. Non-insulin Injectable drugs (Value and Volume 2012-2024)
      • 5.1.3.1. GLP-1 Receptor Agonists
      • 5.1.3.1.1. Victoza (Liraglutide)
      • 5.1.3.1.2. Byetta (Exenatide)
      • 5.1.3.1.3. Bydureon (Exenatide)
      • 5.1.3.1.4. Trulicity (Dulaglutide)
      • 5.1.3.1.5. Lyxumia (Lixisenatide)
      • 5.1.3.2. Amylin Analogue
      • 5.1.3.2.1. Symlin (Pramlintide)
    • 5.1.4. Combination Drugs
      • 5.1.4.1. Combination Insulin
      • 5.1.4.1.1. NovoMix (Biphasic Insulin Aspart)
      • 5.1.4.1.2. Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 5.1.4.1.3. Xultophy (Insulin Degludec and Liraglutide)
      • 5.1.4.2. Oral Combination
      • 5.1.4.2.1. Janumet (Sitagliptin and Metformin HCl)
  • 5.2. Geography
    • 5.2.1. North America
      • 5.2.1.1. United States (Value and Volume 2012-2024)
      • 5.2.1.1.1. Oral Anti-diabetic Drugs
      • 5.2.1.1.2. Insulin
      • 5.2.1.1.3. Non-Insulin Injectable Drugs
      • 5.2.1.1.4. Combination Drugs
      • 5.2.1.1.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.1.2. Canada (Value and Volume 2012-2024)
      • 5.2.1.2.1. Oral Anti-diabetic Drugs
      • 5.2.1.2.2. Insulin
      • 5.2.1.2.3. Non-Insulin Injectable Drugs
      • 5.2.1.2.4. Combination Drugs
      • 5.2.1.2.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.1.3. Rest of North America (Value and Volume 2012-2024)
      • 5.2.1.3.1. Oral Anti-diabetic Drugs
      • 5.2.1.3.2. Insulin
      • 5.2.1.3.3. Non-Insulin Injectable Drugs
      • 5.2.1.3.4. Combination Drugs
      • 5.2.1.3.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.2. Europe
      • 5.2.2.1. France (Value and Volume 2012-2024)
      • 5.2.2.1.1. Oral Anti-diabetic Drugs
      • 5.2.2.1.2. Insulin
      • 5.2.2.1.3. Non-Insulin Injectable Drugs
      • 5.2.2.1.4. Combination Drugs
      • 5.2.2.1.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.2. Germany (Value and Volume 2012-2024)
      • 5.2.2.2.1. Oral Anti-diabetic Drugs
      • 5.2.2.2.2. Insulin
      • 5.2.2.2.3. Non-Insulin Injectable Drugs
      • 5.2.2.2.4. Combination Drugs
      • 5.2.2.2.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.3. Italy (Value and Volume 2012-2024)
      • 5.2.2.3.1. Oral Anti-diabetic Drugs
      • 5.2.2.3.2. Insulin
      • 5.2.2.3.3. Non-Insulin Injectable Drugs
      • 5.2.2.3.4. Combination Drugs
      • 5.2.2.3.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.4. Spain (Value and Volume 2012-2024)
      • 5.2.2.4.1. Oral Anti-diabetic Drugs
      • 5.2.2.4.2. Insulin
      • 5.2.2.4.3. Non-Insulin Injectable Drugs
      • 5.2.2.4.4. Combination Drugs
      • 5.2.2.4.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.5. United Kingdom (Value and Volume 2012-2024)
      • 5.2.2.5.1. Oral Anti-diabetic Drugs
      • 5.2.2.5.2. Insulin
      • 5.2.2.5.3. Non-Insulin Injectable Drugs
      • 5.2.2.5.4. Combination Drugs
      • 5.2.2.5.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.6. Russia (Value and Volume 2012-2024)
      • 5.2.2.6.1. Oral Anti-diabetic Drugs
      • 5.2.2.6.2. Insulin
      • 5.2.2.6.3. Non-Insulin Injectable Drugs
      • 5.2.2.6.4. Combination Drugs
      • 5.2.2.6.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.7. Rest of Europe (Value and Volume 2012-2024)
      • 5.2.2.7.1. Oral Anti-diabetic Drugs
      • 5.2.2.7.2. Insulin
      • 5.2.2.7.3. Non-Insulin Injectable Drugs
      • 5.2.2.7.4. Combination Drugs
      • 5.2.2.7.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.3. Latin America
      • 5.2.3.1. Mexico (Value and Volume 2012-2024)
      • 5.2.3.1.1. Oral Anti-diabetic Drugs
      • 5.2.3.1.2. Insulin
      • 5.2.3.1.3. Non-Insulin Injectable Drugs
      • 5.2.3.1.4. Combination Drugs
      • 5.2.3.1.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.3.2. Brazil (Value and Volume 2012-2024)
      • 5.2.3.2.1. Oral Anti-diabetic Drugs
      • 5.2.3.2.2. Insulin
      • 5.2.3.2.3. Non-Insulin Injectable Drugs
      • 5.2.3.2.4. Combination Drugs
      • 5.2.3.2.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.3.3. Rest of Latin America (Value and Volume 2012-2024)
      • 5.2.3.3.1. Oral Anti-diabetic Drugs
      • 5.2.3.3.2. Insulin
      • 5.2.3.3.3. Non-Insulin Injectable Drugs
      • 5.2.3.3.4. Combination Drugs
      • 5.2.3.3.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.4. Asia-Pacific
      • 5.2.4.1. Japan (Value and Volume 2012-2024)
      • 5.2.4.1.1. Oral Anti-diabetic Drugs
      • 5.2.4.1.2. Insulin
      • 5.2.4.1.3. Non-Insulin Injectable Drugs
      • 5.2.4.1.4. Combination Drugs
      • 5.2.4.1.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.2. South Korea (Value and Volume 2012-2024)
      • 5.2.4.2.1. Oral Anti-diabetic Drugs
      • 5.2.4.2.2. Insulin
      • 5.2.4.2.3. Non-Insulin Injectable Drugs
      • 5.2.4.2.4. Combination Drugs
      • 5.2.4.2.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.3. China (Value and Volume 2012-2024)
      • 5.2.4.3.1. Oral Anti-diabetic Drugs
      • 5.2.4.3.2. Insulin
      • 5.2.4.3.3. Non-Insulin Injectable Drugs
      • 5.2.4.3.4. Combination Drugs
      • 5.2.4.3.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.4. India (Value and Volume 2012-2024)
      • 5.2.4.4.1. Oral Anti-diabetic Drugs
      • 5.2.4.4.2. Insulin
      • 5.2.4.4.3. Non-Insulin Injectable Drugs
      • 5.2.4.4.4. Combination Drugs
      • 5.2.4.4.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.5. Australia (Value and Volume 2012-2024)
      • 5.2.4.5.1. Oral Anti-diabetic Drugs
      • 5.2.4.5.2. Insulin
      • 5.2.4.5.3. Non-Insulin Injectable Drugs
      • 5.2.4.5.4. Combination Drugs
      • 5.2.4.5.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.6. Vietnam (Value and Volume 2012-2024)
      • 5.2.4.6.1. Oral Anti-diabetic Drugs
      • 5.2.4.6.2. Insulin
      • 5.2.4.6.3. Non-Insulin Injectable Drugs
      • 5.2.4.6.4. Combination Drugs
      • 5.2.4.6.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.7. Malaysia (Value and Volume 2012-2024)
      • 5.2.4.7.1. Oral Anti-diabetic Drugs
      • 5.2.4.7.2. Insulin
      • 5.2.4.7.3. Non-Insulin Injectable Drugs
      • 5.2.4.7.4. Combination Drugs
      • 5.2.4.7.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.8. Indonesia (Value and Volume 2012-2024)
      • 5.2.4.8.1. Oral Anti-diabetic Drugs
      • 5.2.4.8.2. Insulin
      • 5.2.4.8.3. Non-Insulin Injectable Drugs
      • 5.2.4.8.4. Combination Drugs
      • 5.2.4.8.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.9. Philippines (Value and Volume 2012-2024)
      • 5.2.4.9.1. Oral Anti-diabetic Drugs
      • 5.2.4.9.2. Insulin
      • 5.2.4.9.3. Non-Insulin Injectable Drugs
      • 5.2.4.9.4. Combination Drugs
      • 5.2.4.9.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.10. Thailand (Value and Volume 2012-2024)
      • 5.2.4.10.1. Oral Anti-diabetic Drugs
      • 5.2.4.10.2. Insulin
      • 5.2.4.10.3. Non-Insulin Injectable Drugs
      • 5.2.4.10.4. Combination Drugs
      • 5.2.4.10.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.11. Rest of Asia-Pacific (Value and Volume 2012-2024)
      • 5.2.4.11.1. Oral Anti-diabetic Drugs
      • 5.2.4.11.2. Insulin
      • 5.2.4.11.3. Non-Insulin Injectable Drugs
      • 5.2.4.11.4. Combination Drugs
      • 5.2.4.11.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.5. Middle East & Africa
      • 5.2.5.1. Saudi Arabia (Value and Volume 2012-2024)
      • 5.2.5.1.1. Oral Anti-diabetic Drugs
      • 5.2.5.1.2. Insulin
      • 5.2.5.1.3. Non-Insulin Injectable Drugs
      • 5.2.5.1.4. Combination Drugs
      • 5.2.5.1.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.2. Iran (Value and Volume 2012-2024)
      • 5.2.5.2.1. Oral Anti-diabetic Drugs
      • 5.2.5.2.2. Insulin
      • 5.2.5.2.3. Non-Insulin Injectable Drugs
      • 5.2.5.2.4. Combination Drugs
      • 5.2.5.2.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.3. Egypt (Value and Volume 2012-2024)
      • 5.2.5.3.1. Oral Anti-diabetic Drugs
      • 5.2.5.3.2. Insulin
      • 5.2.5.3.3. Non-Insulin Injectable Drugs
      • 5.2.5.3.4. Combination Drugs
      • 5.2.5.3.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.4. Oman (Value and Volume 2012-2024)
      • 5.2.5.4.1. Oral Anti-diabetic Drugs
      • 5.2.5.4.2. Insulin
      • 5.2.5.4.3. Non-Insulin Injectable Drugs
      • 5.2.5.4.4. Combination Drugs
      • 5.2.5.4.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.5. South Africa (Value and Volume 2012-2024)
      • 5.2.5.5.1. Oral Anti-diabetic Drugs
      • 5.2.5.5.2. Insulin
      • 5.2.5.5.3. Non-Insulin Injectable Drugs
      • 5.2.5.5.4. Combination Drugs
      • 5.2.5.5.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.6. Rest of Middle & Africa (Value and Volume 2012-2024)
      • 5.2.5.6.1. Oral Anti-diabetic Drugs
      • 5.2.5.6.2. Insulin
      • 5.2.5.6.3. Non-Insulin Injectable Drugs
      • 5.2.5.6.4. Combination Drugs
      • 5.2.5.6.5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

6. MARKET INDICATORS

  • 6.1. Type 1 Diabetes Population (2012-2024)
  • 6.2. Type 2 Diabetes Population (2012-2024)

7. COMPETITIVE LANDSCAPE

  • 7.1. COMPANY PROFILES
    • 7.1.1. Novo Nordisk
    • 7.1.2. Sanofi
    • 7.1.3. Eli Lilly
    • 7.1.4. Takeda
    • 7.1.5. Pfizer
    • 7.1.6. Janssen Pharmaceuticals
    • 7.1.7. Astellas
    • 7.1.8. Boehringer Ingelheim
    • 7.1.9. Merck and Co.
    • 7.1.10. AstraZeneca
    • 7.1.11. Bristol Myers Squibb
    • 7.1.12. Novartis
  • 7.2. COMPANY SHARE ANALYSIS
    • 7.2.1. Novo Nordisk
    • 7.2.2. Sanofi
    • 7.2.3. Eli Lilly
    • 7.2.4. AstraZeneca
    • 7.2.5. Astellas
    • 7.2.6. Janssen Pharmaceuticals
    • 7.2.7. Merck and Co.
    • 7.2.8. Others

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top